Clinical pharmacology and use of microtubule-targeting agents in cancer therapy
- PMID: 18085232
- DOI: 10.1007/978-1-59745-442-1_15
Clinical pharmacology and use of microtubule-targeting agents in cancer therapy
Abstract
The microtubule-targeting agents have made significant contributions to cancer therapy over the past 50 years. The vinca alkaloids and taxanes have been used to treat a broad range of malignancies, including leukemias and lymphomas and many types of solid tumors. The taxanes have been frequently used in the treatment of advanced ovarian, breast, lung, head and neck, and prostate cancer, and they are increasingly being used in early stage disease. This chapter reviews the pharmacology, clinical indications, and toxicities associated with the vinca alkaloids and taxanes.
Similar articles
-
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics.Pharmacol Ther. 1991 Oct;52(1):35-84. doi: 10.1016/0163-7258(91)90086-2. Pharmacol Ther. 1991. PMID: 1687171 Review.
-
Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.PLoS One. 2017 Aug 7;12(8):e0182400. doi: 10.1371/journal.pone.0182400. eCollection 2017. PLoS One. 2017. PMID: 28787019 Free PMC article.
-
Microtubule-targeting drugs and personalization of cancer treatment.Pharmacogenomics. 2011 Apr;12(4):449-51. doi: 10.2217/pgs.11.12. Pharmacogenomics. 2011. PMID: 21521015 No abstract available.
-
Targeting microtubules for cancer chemotherapy.Curr Med Chem Anticancer Agents. 2005 Jan;5(1):65-71. doi: 10.2174/1568011053352569. Curr Med Chem Anticancer Agents. 2005. PMID: 15720262 Review.
-
Microtubule destabilising agents: far more than just antimitotic anticancer drugs.Br J Clin Pharmacol. 2017 Feb;83(2):255-268. doi: 10.1111/bcp.13126. Epub 2016 Oct 18. Br J Clin Pharmacol. 2017. PMID: 27620987 Free PMC article. Review.
Cited by
-
Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms.Cancers (Basel). 2022 Dec 10;14(24):6080. doi: 10.3390/cancers14246080. Cancers (Basel). 2022. PMID: 36551566 Free PMC article.
-
Anaphase catastrophe is a target for cancer therapy.Clin Cancer Res. 2011 Mar 15;17(6):1218-22. doi: 10.1158/1078-0432.CCR-10-1178. Epub 2011 Feb 2. Clin Cancer Res. 2011. PMID: 21288923 Free PMC article.
-
TaxKB: a knowledge base for new taxane-related drug discovery.BioData Min. 2015 Jun 28;8:19. doi: 10.1186/s13040-015-0053-5. eCollection 2015. BioData Min. 2015. PMID: 26131021 Free PMC article.
-
PPARgamma Inhibitors as Novel Tubulin-Targeting Agents.PPAR Res. 2008;2008:785405. doi: 10.1155/2008/785405. PPAR Res. 2008. PMID: 18509498 Free PMC article.
-
Targeting mitotic pathways for endocrine-related cancer therapeutics.Endocr Relat Cancer. 2017 Sep;24(9):T65-T82. doi: 10.1530/ERC-17-0080. Epub 2017 Jun 14. Endocr Relat Cancer. 2017. PMID: 28615236 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous